Default company panoramic image

AKL Technologies Ltd

"Clinic-to-lab" model: synthetic drug candidates are developed from established natural products.where safety & efficacy is established

  • Stage Product In Development
  • Industry Biotechnology
  • Location Stevenage, England, GB
  • Currency USD
  • Founded May 2001
  • Employees 5
  • Website

Company Summary

AKL is developing APPA to address a major unmet need in treating osteoarthritis. Originally naturally derived, APPA is now a fully synthetic drug that has shown encouraging results in controlled animal studies and has favourable anecdotal observations in animal and human subjects. AKL’s “clinic-to-lab” model provides rare insights into drug performance before embarking on conventional development, leading to a significant reduction in risk.


  • Default avatar
    Sonya Glasson BVSc

    Dr. Sonya Glasson, Chief Scientific Officer brings clinical expertise in OA. She previously led a team of musculoskeletal scientists, developing therapeutics for osteoarthritis (OA), muscle anabolics, cartilage, tendon and fracture repair at Wyeth Laboratories.

  • Default avatar
    David Miles
    Head of Business Development

    David Miles is a BioPharma commercial executive with experience at all product life cycle stages at country, region and global level. A former Head of Inflammation for Pfizer in Europe.

  • Default avatar
    Nicholas Larkins BVSc DSc MRCVS

    Dr Nicholas Larkins, founder, is in charge of R&D and has extensive experience with phyto-pharmaceuticals in immunology.

  • Default avatar
    David Sharples

    David Sharples, CEO and founder, has experience with multiple start-up companies recruiting and supervising strong management teams.

  • Default avatar
    Professor David Price

    Prof David Price MA MB Bchir FRCGP David Price is the Primary Care Respiratory Society Professor of Primary Care Respiratory Medicine at the University of Aberdeen, Scotland and Affiliate Associate Professor in the Department of General Practice at the University of Adelaide in Australia as well as holding an honorary chair at the University of East Anglia. He was until recently the director for the Comprehensive Local Research Network in Norfolk